Precision Virologics has optioned the rights to offer the intranasal vaccine in the U.S., Europe, and Japan, and Bharat has obtained a license for all other markets.

In mouse studies, a single nasal dose has shown protection against the virus. Based on these findings, the U.S. National Institutes of Health is advancing studies in nonhuman primates, according to the companies.

Thomas Jefferson University selected to advance CoraVax
The Commonwealth of Pennsylvania has awarded Thomas Jefferson University a grant for the development of CoraVax, a novel COVID-19 vaccine.

Intravacc forms public-private partnership for intranasal COVID-19 vaccine
Intravacc announced that it is partnering with Wageningen Bioveterinary Research and Utrecht University for the development of an intranasal vaccine against...

Bharat, TJU partnering on COVID-19 vaccine
Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...